Sachdev P. The current status of tardive dyskinesia. Aust N Z J Psychiatry. 2000;34:355–69.
CAS
Article
PubMed
Google Scholar
Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589–98.
Article
PubMed
Google Scholar
Sigwald J, Bouttier D, Raymondeaud C, Piot C. 4 Cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics. Rev Neurol (Paris) 1959; Jun;100:751–5
CAS
Google Scholar
Faurbye A, Rasch PJ, Petersen PB, Brandborg G, Pakkenberg H. NEUROLOGICAL SYMPTOMS IN PHARMACOTHERAPY OF PSYCHOSES. Acta Psychiatr Scand. 1964; 40:10–27
Article
Google Scholar
American Psychiatric Association (APA): 2013; DSM-5
Aquino CCH, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20(Suppl 1):113–7.
Article
Google Scholar
Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J. 2004;80:527–34.
CAS
Article
PubMed
PubMed Central
Google Scholar
Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18:197–214.
CAS
Article
PubMed
Google Scholar
Bhidayasiri R, Bronstein JM. Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Med Hypotheses. 2005;64:941–5.
Article
PubMed
Google Scholar
Stacy M, Jankovic J. Tardive Dyskinesia. Curr Opin Neurol Neurosurg. 1991;4:343–9.
Google Scholar
Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21(5):589–98.
Article
PubMed
Google Scholar
Eberhard J, Lindström E, Levander S. Tardive dyskinesia and antipsychotics: a 5‑year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol. 2006;21:35–42.
Article
PubMed
Google Scholar
Cavallaro R, Regazzetti MG, Mundo E, Brancato V, Smeraldi E. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence. Neuropsychopharmacology. 1993;8:233–9.
CAS
Article
PubMed
Google Scholar
Rittmannsberger H. Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics. Psychiatr Danub. 2008;20(4):461–5.
PubMed
Google Scholar
Kane JM. et al. Tardive Dyskinesia: a task force report of the American Psychiatric Association. Washington D.C.: American Psychiatric Association; 1992.
Google Scholar
Fleischhacker WW, Widschwendter C. Extrapyramidal side-effects: avoidance, diagnosis and treatment. Psychiatr Prax. 2005;32(Suppl.1):25–30.
Article
Google Scholar
Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703–14.
PubMed
Google Scholar
Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65(Suppl.9):21–4.
CAS
PubMed
Google Scholar
Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(Suppl.9):16–20.
CAS
PubMed
Google Scholar
Bhidayasiri R. Boonyawairoj, Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011;87:132–41.
Article
PubMed
Google Scholar
Sethi KD, Morgan JC. Drug induced movement disorders. In: Jankovics JJ, Tolosa E (Hrsg.). Parkinson’s disease and movement disorders. New York: Lippincott Williams & Wilkins; 2007. S. 394–408.
Google Scholar
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6.
Article
PubMed
Google Scholar
Winsberg BG, Hurwic MJ, Perel J. Neurochemistry of withdrawal emergent symptoms in children. Psychopharmacol Bull. 1977;13:38–40.
CAS
PubMed
Google Scholar
Klawans HL Jr., McKendall RR. Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia. J Neurol Sci. 1971;14:189–92.
Article
PubMed
Google Scholar
Klawans HL Jr., Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm. 1972;33:235–46.
Article
PubMed
Google Scholar
Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med. 1980;10:55–72.
CAS
Article
PubMed
Google Scholar
Calabresi P, de Murtas M, Mercuri NB, Bernardi G. Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. Ann Neurol. 1992;31:366–73.
CAS
Article
PubMed
Google Scholar
Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol. 2000;61:525–41.
CAS
Article
PubMed
Google Scholar
Burger M, Fachinetto R, Calegari L, Paixão MW, Braga AL, Rocha JB. Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide. Brain Res Bull. 2004;64:339–45.
CAS
Article
PubMed
Google Scholar
Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L‑dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biol Psychiatry. 1993;34:713–38.
CAS
Article
PubMed
Google Scholar
Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry. 2000;5:410–7.
CAS
Article
PubMed
Google Scholar
Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH, Wang JJ, Lu XQ. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin. 2006;27:328–32.
CAS
Article
PubMed
Google Scholar
Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, Lerer B, Nimagaonkar VL, Thelma BK. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 2005;5:60–9.
CAS
Article
PubMed
Google Scholar
Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27(10):1205–15.
Article
PubMed
Google Scholar
Andreassen OA, Finsen B, Ostergaard K, Sørensen JC, West MJ, Jørgensen HA. The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Neuroscience. 1999;88:27–35.
CAS
Article
PubMed
Google Scholar
Gunne LM, Andren PE. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol. 1993;16:90–5.
CAS
Article
PubMed
Google Scholar
Cloud JL, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–76.
CAS
Article
PubMed
Google Scholar
Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585–92.
CAS
Article
PubMed
Google Scholar
AMG §8 Abs. 1; BGBI 1983/185 idF BGBI I 2005/153
World Medical Association. WMA declaration of Helsinki – ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html. Zugegriffen: 23. Nov 2015.
Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord. 2009;24(16):2309–15.
Article
PubMed
Google Scholar
Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334–49.
Article
PubMed
Google Scholar
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1‑year studies. Am J Psychiatry. 2004;161:414–25.
Article
PubMed
Google Scholar
Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, SOHO Study Group. Effects of antipsychotic treatment on tardive dyskinesia: a 6‑month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005;66:1130–3.
Article
PubMed
Google Scholar
Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48:379–84.
CAS
Article
PubMed
Google Scholar
Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry. 2006;18:57–62.
Article
PubMed
Google Scholar
Friedmann JH. Atypical antipsychotics in the EPS-vulnerable patient. Psychoneuroendocinology. 2003;28(suppl 1):39–51.
Article
Google Scholar
EMA 2013: Article 31 of Directive 2001/83/EC
Saifee TA, Edwards MJ. Tardive movement disorders: a practical approach. Pract Neurol. 2011;11(6):341–8.
Article
PubMed
Google Scholar
Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585–92.
CAS
Article
PubMed
Google Scholar
Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271–5.
CAS
Article
PubMed
Google Scholar
Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA, American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–9.
Article
PubMed
Google Scholar
Gardos G, Cole JO, Rapkin RM, LaBrie RA, Baquelod E, Moore P, Sovner R, Doyle J. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry. 1984;41:1030–5.
CAS
Article
PubMed
Google Scholar
Branchey MH, Branehey LB, Richardson MA. Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]. Psychopharmacol Bull. 1981;17:118–20.
CAS
PubMed
Google Scholar
Angus S, Sugars J, Boltezar R, Koskewich S, Schneider NM. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.
CAS
Article
PubMed
Google Scholar
Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147:445–51.
CAS
Article
PubMed
Google Scholar
Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72:615–21.
Article
PubMed
Google Scholar
Zhang XY, Zhang WF, Zhou DF, da Chen C, Xiu MH, Wu HR, Haile CN, Kosten TA, Kosten TR. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry. 2012;72(8):700–6.
CAS
Article
PubMed
Google Scholar
Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–54.
CAS
Article
PubMed
Google Scholar
Factor SA. Propranolol therapy for tardive dyskinesia revisited. Mov Disord. 2012;27(13):1703.
Article
PubMed
Google Scholar
Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68(7):1031–7.
CAS
Article
PubMed
Google Scholar
Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry. 2012;73(11):1434–8.
Article
PubMed
Google Scholar